K Number
K030179
Device Name
MEDISISS PHACOEMULSIFICATION TIPS/NEEDLES
Date Cleared
2003-01-24

(7 days)

Product Code
Regulation Number
886.4670
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
The MediSISS™ Reprocessed Phacoemulsification Tips/Needles are intended to emulsify and excise cataract tissue in ophthalmic microsurgical procedures.
Device Description
Reprocessed Phacoemulsification Tips/Needles are specifically designed to be used to emulcataractous lens material and remove it from the eye (phacoemulsification). Electric energy is generated in the Phacoemulsification System, delivered in a headpiece, and is finally converted to ultrasonic energy delivered through a hollow titanium needle or tip. Irrigation fluid is delivered to the eye via a combination of an irrigation sleeve over the handpiece tip. The emulsified lens material is aspirated out of the eye through the center of the headpiece /tip assembly. The headpieces are routinely used repeatedly in multiple surgical procedures, while the tips are marketed as single use only.
More Information

K012637, K012579, K0126098

No
The device description and performance studies focus on the reprocessing and mechanical function of phacoemulsification tips/needles, with no mention of AI or ML.

Yes

The device actively treats a medical condition (cataract tissue removal) through direct physical intervention (emulsification and excision), aligning with the definition of a therapeutic device.

No

Explanation: The device is a surgical tool used for emulsifying and excising cataract tissue. It is involved in treatment (phacoemulsification), not diagnosis.

No

The device is a physical medical device (reprocessed phacoemulsification tips/needles) used in ophthalmic surgery, not a software-only device. The description details hardware components and physical processes like sterilization and mechanical testing.

No, this device is not an IVD (In Vitro Diagnostic).

Here's why:

  • Intended Use: The intended use is to "emulsify and excise cataract tissue in ophthalmic microsurgical procedures." This is a surgical procedure performed directly on the patient's eye, not a test performed on a sample taken from the body.
  • Device Description: The description details a device that uses ultrasonic energy to break down tissue and remove it from the eye. This is a therapeutic/surgical function, not a diagnostic test.
  • Lack of IVD Characteristics: The description does not mention analyzing biological samples (blood, urine, tissue, etc.) or providing information about a patient's health status based on such analysis, which are hallmarks of IVD devices.

The device is a surgical instrument used during a procedure, not a tool for diagnosing a condition before or after a procedure by analyzing samples.

N/A

Intended Use / Indications for Use

The MediSISS™ Reprocessed Phacoemulsification Tips/Needles are intended to emulsify and excise cataract tissue in ophthalmic microsurgical procedures.

Product codes

86 NKX, HQC

Device Description

Reprocessed Phacoemulsification Tips/Needles are specifically designed to be used to emulcataractous lens material and remove it from the eye (phacoemulsification). Electric energy is generated in the Phacoemulsification System, delivered in a headpiece, and is finally converted to ultrasonic energy delivered through a hollow titanium needle or tip.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Cataract tissue in ophthalmic refers to the eye.

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Cleaning, sterilization, packaging validations, and visual/mechanical testing demonstrate that the devices are equivalent and continue to be safe and effective for their intended use.
MediSISS™ Reprocessed Phacoemulsification Tips/Needles undergo mechanical testing to demonstrate that the parts do not change in function. Process validation testing was done to validate the cleaning and sterilization procedures as well as the device's packaging.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s)

K981103, K861380, K832836, K902798, K911808, K980292

Reference Device(s)

K012637, K012579, K0126098

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 886.4670 Phacofragmentation system.

(a)
Identification. A phacofragmentation system is an AC-powered device with a fragmenting needle intended for use in cataract surgery to disrupt a cataract with ultrasound and extract the cataract.(b)
Classification. Class II.

0

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized representation of human profiles facing right, stacked on top of each other. The profiles are rendered in black and have a flowing, abstract design. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the graphic.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

NOV 1 2004

MediSISS™, Inc. c/o Ms. Brandi James Regulatory Specialist 2747 SW 6th Street Redmond, OR 97756

Re: K030179 - Supplemental Validation Submission Trade/Device Name: See Enclosed List Regulation Number: 21 CFR 886.4670 Regulation Name: Phacofragmentation System Regulatory Class: Class II Product Code: 86 NKX Dated: January 15, 2003 Received: January 17, 2003

Dear Ms. James:

The above-referenced premarket notification (510(k)) was cleared by the Office of Device Evaluation (ODE) on January 24, 2003. We have received your supplemental validation data as required for reprocessed single-use devices by the Medical Device User Fee and Modernization Act of 2002. After reviewing your supplemental validation data, we have determined the devices listed in the enclosure accompanying this letter are substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market these devices, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your devices are classified (see above) into either class II (Special Controls) or class III (PMA) they may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your devices in the Federal Register.

1

Page 2- Ms. Brandi James

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your devices comply with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's applicable requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

The FDA finding of substantial equivalence of your devices to legally marketed predicate devices results in classification for your devices and thus, permits you to legally market the devices. This letter will allow you to continue marketing the devices listed in the enclosure accompanying this letter.

If you desire specific advice for your devices on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours,

David Dr. Wajsble

A. Ralph Rosenthal, M.D.

A. Ralph Rosenthal, M.D. Director Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure - Attachment 1 - List of Catalog Model Numbers

2

ATTACHMENT 1

ALCON Laboratories, Inc.'s Series 20000™ Legacy® Phacoemulsification Tips Catalog Model Numbers To Be Reprocessed By MediSISS, Inc.

30RTS0.9mm, MicroTip™, Purple30° Round
45RTS0.9mm, MicroTip™, Purple45° Round
30KTS0.9mm, MicroTip™, Purple30° Kelman®
45KTS0.9mm, MicroTip™, Purple45° Kelman®
80657900190.9mm, ABS™ MicroTip™, Purple0° Round
80657900200.9mm, ABS™ MicroTip™, Purple30° Round
80657900210.9mm, ABS™ MicroTip™, Purple45° Round
80657900220.9mm, ABS™ MicroTip™, Purple30° Kelman®
80657900230.9mm, ABS™ MicroTip™, Purple45° Kelman®
80657408360.9mm, ABS™ MicroTip™, Purple0° Round, Flared
80657408370.9mm, ABS™ MicroTip™, Purple30° Round, Flared
80657408380.9mm, ABS™ MicroTip™, Purple45° Round, Flared
80657408390.9mm, ABS™ MicroTip™, Purple30° Kelman®, Flared
80657408400.9mm, ABS™ MicroTip™, Purple45° Kelman®, Flared
15RT1.1mm, TurboSONICS® Standard U/S Tip, Blue15° Round
30RT1.1mm, TurboSONICS® Standard U/S Tip, Blue30° Round
45RT1.1mm, TurboSONICS® Standard U/S Tip, Blue45° Round
30KT1.1mm, TurboSONICS® Standard U/S Tip, Blue30° Kelman®
45KT1.1mm, TurboSONICS® Standard U/S Tip, Blue45° Kelman®
80657407911.1mm, TurboSONICS® Standard ABS™ Tip, Blue0° Round
80657407921.1mm, TurboSONICS® Standard ABS™ Tip, Blue30° Round
80657407931.1mm, TurboSONICS® Standard ABS™ Tip, Blue45° Round
80657407941.1mm, TurboSONICS® Standard ABS™ Tip, Blue30° Kelman®
80657407951.1mm, TurboSONICS® Standard ABS™ Tip, Blue45° Kelman®
80657408051.1mm, TurboSONICS® Standard ABS™ Tip, Blue0° Round, Flared
80657408061.1mm, TurboSONICS® Standard ABS™ Tip, Blue30° Round, Flared
80657408071.1mm, TurboSONICS® Standard ABS™ Tip, Blue45° Round, Flared
80657408081.1mm, TurboSONICS® Standard ABS™ Tip, Blue30° Kelman®, Flared
80657408091.1mm, TurboSONICS® Standard ABS™ Tip, Blue45° Kelman®, Flared

..............................................................................................................................................................................

3

Tichesticons Tor USS

Page 1 of 1

510(k) Number (if known): K030179

Device Name: MediSISS™ Reprocessed Phacoemulsification Tips/Needles

Indications for Use:

ﻣﻠﻔﺎﺕ ﺩﺭ

The MediSISS™ Reprocessed Phacoemulsification Tips/Needles are intended to emulsify and excise cataract tissue in ophthalmic microsurgical procedures.

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use
(Per 21 CFR 801.109)

OR

Treuth Been
(Division Sign-Off)

Over-The-Counter Use

(Optional Format 1-2-96)

MediSISS™

723 Curtis Court, Sisters, OR 97759

December 27th, 200

4

K030179 Page 34 of 36

submitted by

JAN 2 4 2003

MediSISS, Inc. P.O. 2060 723 Curtis Court Sisters, OR 97759 Phone: (800)-860-9482 Fax: (541) 549-4527 Email: mabarker(@medisissinc.com

Contact Person:Mary Ann Barker
Device Trade Names:MediSISS TM Reprocessed Phacoemulsification Tips/Needles
Common Names:Reprocessed Phacoemulsification Tips/Needles
Classification Names:Ophthalmic Devices, Phacofragmentation Needle, Electric, per
21 CFR §886.4670; Product Code: HQC; Regulatory Class: II

Identification of a Legally Marketed Predicate Device

The MediSISS™ Reprocessed Phacoemulsification Tips/Needles are substantially equivalent to the Phacoemulsification Tips/Needles as listed below:

Company

510(k) #

AlconK981103, K861380, K832836, K902798,
K911808, K980292

They are also similar to the reprocessed hot biopsy forceps reprocessed by Alliance Corporation and legally marketed and distributed pursuant to Reprocessed Phacoemulsification Tips 510(k) K012637. Likewise, SterilMed, Inc. Reprocessed Phaco Tips: - 510(k) K012579; and Vanguard Medical Concepts, Inc Vanguard Reprocessed Phacoemulsification Needles/Tips, 510(k) K0126098

Device Description

Reprocessed Phacoemulsification Tips/Needles are specifically designed to be used to emulcataractous lens material and remove it from the eye (phacoemulsification). Electric energy is generated in the Phacoemulsification System, delivered in a headpiece, and is finally converted to ultrasonic energy delivered through a hollow titanium needle or tip.

5

Irrigation fluid is delivered to the eye via a combination of an irrigation sleeve over the handpiece tip. The emulsified lens material is aspirated out of the eye through the center of the headpiece /tip assembly. The headpieces are routinely used repeatedly in multiple surgical procedures, while the tips are marketed as single use only. However, devices that the OEM has listed as predicates on their 510(k) i.e.: K981103, are reusable. Also, according to Alcons 510(k) K981103, the OEM took a single-use device and resubmitted it to clear for multiple reprocessing (usage up to 20 surgical procedures). This 510(k) was cleared to market on 6/23/98.

Intended Use

The MediSISS™ Reprocessed Phacoemulsification Tips are designed to emulsify and excise cataract tissue in ophthalmic microsurgical procedures.

Summary of Technological Characteristics

The intended use and technological features of the reprocessed devices do not differ from the legally marketed predicate device(s). Both the reprocessed devices(s) and the predicate device(s) have the same materials and product design. There are no changes to the claims, intended use, clinical applications, patient populations, performance specifications, or methods of operation. The technological characteristics of the reprocessed phacoemulsification tips/needles are the same as those of the legally marketed predicate devices. The technological characteristics of the reprocessed phacoemulsification tips/needles are the same as those of the legally marketed predicate devices. In addition the MediSISS™ manufacturing process includes 100 % visual and mechanical testing of all products prior to packaging, labeling, and sterilization.

Summary of Performance Data

The MediSISS™ Reprocessed Phacoemulsification Tips/Needles comply with the following standards, practices, and guidance's:

Sterilization Validation and EO Residuals:

  • ANSI/AAMI/ISO 11135-1994, Medical Devices----Validation and Routine Control of . Ethylene Oxide Sterilization
  • ANSI/AAMI/ISO 10993-7:1995, Biological Evaluation of Medical Devices-Part 7: . Ethylene oxide sterilization residual.

Cleaning Validation:

  • AAMI RDS0TIR No. 12-1994. Designing, Testing, and Labeling Reusable Medical . Devices for Reprocessing in Health Care Facilities: A guide for Device Manufactures. Association for the Advancement of Medical Instrumentation, Arlington, VA.Food and Drug Administration, 1996.

6

  • Labeling Reusable Medical Devices for Reprocessing in Health Care Facilities: FDA . Reviewer Guidance, Office of Device Evaluation. FDA, Washington, D.C.
    Cleaning, sterilization, packaging validations, and visual/mechanical testing demonstrate that the devices are equivalent and continue to be safe and effective for their intended use.

MediSISS™ Reprocessed Phacoemulsification Tips/Needles undergo mechanical testing to demonstrate that the parts do not change in function. Process validation testing was done to validate the cleaning and sterilization procedures as well as the device's packaging.

Conclusion

Since the MediSISS™ Reprocessed Phacoemulsification Tips/Needles meet the requirements of the stated standards and embody technological characteristics identical to the predicate device, we believe the device is safe and effective and performs as well as or better than the predicate device. The MediSISS™ Reprocessed Phacoemulsification Tips/Needles will be reprocessed per specifications and good manufacturing practices that ensure the device is safe and effective for its intended use.

In Accordance with the Federal Food, Drug, and cosmetic Act, 21 CFR Part 807 and based on the information provided in this premarket notification, MediSISS™ concludes that the device(s)(Reprocessed Phacoemulsification Tips/Needles) are safe, effectives, and substantially equivalent to the predicate devices as described herein.

This conclusion is based upon the devices' similarities in functional design, materials, indications for use, and methods of construction.